Canton Strategic Holdings (CNTN) Shares Outstanding (Diluted Average) (2022 - 2026)
Canton Strategic Holdings posted quarterly Shares Outstanding (Diluted Average) of $207.7 million for Q1 2026, up 7973.41% year-on-year from $2.6 million in Q1 2025, and up 548.08% on a QoQ basis from $32.0 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 5 years of Shares Outstanding (Diluted Average) data on file, last reported at $207.7 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 7973.41% year-over-year to $207.7 million; the trailing twelve-month figure through Mar 2026 stood at $207.7 million (up 7973.41% YoY), and the FY2025 full-year result was $32.0 million, up 2372.39% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $207.7 million, up from $32.0 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $207.7 million in Q1 2026 and bottomed at $44889.0 in Q2 2023.
- The 5-year median for Shares Outstanding (Diluted Average) is $1.2 million (2024), against an average of $17.5 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) slumped 99.61%; it then surged 7973.41% in 2026.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $452686.0 in 2022, then slumped by 80.76% to $87079.0 in 2023, then jumped by 1388.64% to $1.3 million in 2024, then surged by 2372.39% to $32.0 million in 2025, then jumped by 548.08% to $207.7 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $207.7 million (Q1 2026), $32.0 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | 207.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.71 Mn |
| Dec 31, 2025 | 32.05 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 962,149.00 |
| Mar 31, 2024 | 885,683.00 |
| Dec 31, 2023 | 87,079.00 |
| Sep 30, 2023 | 46,169.00 |
| Jun 30, 2023 | 44,889.00 |
| Mar 31, 2023 | 460,580.00 |
| Dec 31, 2022 | 452,686.00 |
| Sep 30, 2022 | 11.53 Mn |
| Jun 30, 2022 | 11.57 Mn |